Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvie Retout

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Statistics in Medicine|May 9, 2007
Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariatesSylvie Retout, Emmanuelle Comets, Adeline Samson, et al.
Pharmaceutical Research|June 8, 2013
Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokineticsFrançois Pierre Combes, Sylvie Retout, Nicolas Frey, et al.
Diabetes Care|April 16, 2009
Automated ankle-brachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in nondiabetic and diabetic patientsCécile Clairotte, Sylvie Retout, Louis Potier, et al.
The AAPS Journal|March 31, 2018
Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect ModelsSimon Buatois, Sebastian Ueckert, Nicolas Frey, et al.
Clinical Pharmacokinetics|June 7, 2020
Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia ASylvie Retout, Christophe Schmitt, Claire Petry, et al.
Statistics in Medicine|March 2, 2021
cLRT-Mod: An efficient methodology for pharmacometric model-based analysis of longitudinal phase II dose finding studies under model uncertaintySimon Buatois, Sebastian Ueckert, Nicolas Frey, et al.
Clinical Pharmacology and Therapeutics|May 19, 2022
A Pharmacokinetics-Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or BSylvie Retout, Stefan De Buck, Sébastien Jolivet, et al.
Clinical Pharmacology and Therapeutics|January 31, 2022
Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's DiseaseSylvie Retout, Ronald Gieschke, Daniel Serafin, et al.
Clinical Pharmacokinetics|March 12, 2021
Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIIIFredrik Jonsson, Christophe Schmitt, Claire Petry, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 19, 2024
Simulation-based evaluation of the Pharmpy Automatic Model Development tool for population pharmacokinetic modeling in early clinical drug developmentZrinka Duvnjak, Franziska Schaedeli Stark, Valérie Cosson, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Statistics in Medicine|May 9, 2007
Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariatesSylvie Retout, Emmanuelle Comets, Adeline Samson, et al.
Pharmaceutical Research|June 8, 2013
Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokineticsFrançois Pierre Combes, Sylvie Retout, Nicolas Frey, et al.
Diabetes Care|April 16, 2009
Automated ankle-brachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in nondiabetic and diabetic patientsCécile Clairotte, Sylvie Retout, Louis Potier, et al.
The AAPS Journal|March 31, 2018
Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect ModelsSimon Buatois, Sebastian Ueckert, Nicolas Frey, et al.
Clinical Pharmacokinetics|June 7, 2020
Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia ASylvie Retout, Christophe Schmitt, Claire Petry, et al.
Statistics in Medicine|March 2, 2021
cLRT-Mod: An efficient methodology for pharmacometric model-based analysis of longitudinal phase II dose finding studies under model uncertaintySimon Buatois, Sebastian Ueckert, Nicolas Frey, et al.
Clinical Pharmacology and Therapeutics|May 19, 2022
A Pharmacokinetics-Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or BSylvie Retout, Stefan De Buck, Sébastien Jolivet, et al.
Clinical Pharmacology and Therapeutics|January 31, 2022
Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's DiseaseSylvie Retout, Ronald Gieschke, Daniel Serafin, et al.
Clinical Pharmacokinetics|March 12, 2021
Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIIIFredrik Jonsson, Christophe Schmitt, Claire Petry, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 19, 2024
Simulation-based evaluation of the Pharmpy Automatic Model Development tool for population pharmacokinetic modeling in early clinical drug developmentZrinka Duvnjak, Franziska Schaedeli Stark, Valérie Cosson, et al.
Pageof 4